Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment

被引：0
|
作者：
Georg Feldmann
Peter Brossart
Marie von Lilienfeld-Toal
机构：
[1] University Hospital of Bonn,Department of Internal Medicine 3, Center of Integrated Oncology (CIO) Cologne
[2] Jena University Hospital,Bonn
来源：
Annals of Hematology | 2013年 / 92卷
关键词：
White Blood Cell Count; Lenalidomide; Myelodysplastic Syndrome; Hydroxyurea; Azacitidine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1577 / 1579
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
    Ritchie, Ellen K.
    CLINICAL INTERVENTIONS IN AGING, 2012, 7 : 165 - 173
  • [22] Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
    Zeidan, Amer M.
    Borate, Uma
    Pollyea, Daniel A.
    Brunner, Andrew M.
    Roncolato, Fernando
    Garcia, Jacqueline S.
    Filshie, Robin J.
    Odenike, Olatoyosi
    Watson, Anne-Marie
    Krishnadasan, Ravi
    Bajel, Ashish
    Naqvi, Kiran
    Zha, Jiuhong
    Hogdal, Leah
    Zhou, Ying
    Hoffman, David
    Kye, Steve
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [23] A Case Of Azacitidine Induced Interstitial Pneumonitis In A Patient With Myelodysplastic Syndrome (mds)
    Patel, V.
    Sarkar, S.
    Cervellione, K. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [24] Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome
    Adams, CD
    Szumita, PM
    Baroletti, SA
    Lilly, CM
    PHARMACOTHERAPY, 2005, 25 (05): : 765 - 768
  • [25] Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome
    De Luna, Gonzalo
    Darnige, Luc
    Roueff, Stephane
    Peyrard, Thierry
    Pouchot, Jacques
    Arlet, Jean-Benoit
    ANNALS OF HEMATOLOGY, 2020, 99 (03) : 661 - 662
  • [26] Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome
    Hueser, Christopher N.
    Patel, Anjali J.
    PHARMACOTHERAPY, 2007, 27 (12): : 1759 - 1762
  • [27] Novel chromosomal aberration in a patient with myelodysplastic syndrome after therapy with azacitidine
    Athanasiadou, Anastasia
    Papaioannou, George
    Stavroyianni, Niki
    Tsompanakou, Aliki
    Gaitatzi, Maria
    Anagnostopoulos, Achilles
    CHROMOSOME RESEARCH, 2011, 19 : S147 - S147
  • [28] Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome
    Gonzalo De Luna
    Luc Darnige
    Stéphane Roueff
    Thierry Peyrard
    Jacques Pouchot
    Jean-Benoît Arlet
    Annals of Hematology, 2020, 99 : 661 - 662
  • [29] Image Gallery: Pyoderma gangrenosum in a patient with myelodysplastic syndrome treated with azacitidine
    Pardo Pastor, J.
    Redondo Capafons, S.
    March Lopez, P.
    Nicolas Pico, J.
    Pineda, A.
    Marti, J. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (03) : E68 - E68
  • [30] Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Duong, Vu H.
    Lin, Karen
    Reljic, Tea
    Kumar, Ambuj
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06): : 711 - 715
12345